Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom children’s cancer study group (UKCCSG) retrospective review

Messahel, Boo, Taj, Mary M., Hobson, Rachael, Hadzic, Nedim, Ramsey, Alan, Hann, Ian and Pinkerton, Ross (2006) Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom children’s cancer study group (UKCCSG) retrospective review. Leukemia and Lymphoma, 47 12: 2584-2589. doi:10.1080/10428190600908349


Author Messahel, Boo
Taj, Mary M.
Hobson, Rachael
Hadzic, Nedim
Ramsey, Alan
Hann, Ian
Pinkerton, Ross
Title Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom children’s cancer study group (UKCCSG) retrospective review
Journal name Leukemia and Lymphoma   Check publisher's open access policy
ISSN 1042-8194
1029-2403
Publication date 2006-12
Sub-type Article (original research)
DOI 10.1080/10428190600908349
Volume 47
Issue 12
Start page 2584
End page 2589
Total pages 6
Place of publication Chur ; New York, United States
Publisher Harwood Academic Publishers
Language eng
Subject 1103 Clinical Sciences
Formatted abstract
Survival in childhood lymphoproliferative disease (LPD) remains poor, particularly in non-transplant patients. The anti-CD20 antibody rituximab shows promise but data in children is scant. A retrospective study of 22 (aged 11 months to 18 years) children treated with rituximab is presented. Two had primary immunodeficiency, two had prolonged immunosuppression and 18 had post-transplant LPD (eight bone marrow, five liver, four heart, one kidney). Nine patients had multi-organ involvement and 13 single site disease. Seventeen out of 22 had rituximab alone. In 16, a dose of 375 mg/m2 i.v. weekly was used (less in one patient due to renal dysfunction). Twelve patients received four courses and ten patients received one to three courses. Fever was the main side-effect in four. Eight (47%) had single agent response; four complete and four partial. All had other treatment prior to rituximab. Median follow-up was 35 months (range 22 – 47 months). In childhood LPD unresponsive to standard treatment, rituximab showed single agent response and requires further evaluation.
Keyword Rituximab
Childhood
Post-transplant
Lymphoproliferative disease
Immunodeficiency
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 13 Jan 2010, 16:01:56 EST by Simon Utteridge on behalf of Faculty Of Health Sciences